^
    Back
    Association details:
    Biomarker:GNA13 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ICML 2023
    Title:

    EXPLORING DIFFERENTIAL MUTATIONAL DISTRIBUTION BY TARGETED SEQUENCING IN A R-CHOP TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

    Published date:
    06/09/2023
    Excerpt:
    A cohort of 105 de novo DLBCL pts, uniformly treated with first-line R-CHOP, were studied...in the relapse group, GNA13 mutation at diagnosis was more frequent in early relapses than late relapses (43% vs. 0%, Fisher’s Exact without correction, p = 0.03). The presence of GNA13 in the entire cohort showed a trend towards inferior survival.
    DOI:
    https://doi.org/10.1002/hon.3165_505